Showing 381-390 of 3380 results for "".
Can UV Nail Dryers Cause Skin Cancer?
https://practicaldermatology.com/topics/hair-nails/can-uv-nail-dryers-cause-skin-cancer/23898/Alexis Livingston Young, MD, weighs in on the evidence.Skin Reactions: Understanding New Drug Adverse Effects
https://practicaldermatology.com/conferences/aad-summer-2021/skin-reactions-understanding-new-drug-adverse-effects/19975/In addition to needing to stay abreast of new drugs in dermatology, it's important for dermatologists to stay informed about new medications that come to market in general. Vinod Nambudiri, MD, MBA says there are often dermatology-related adverse events that need to be managed. He discusses new cancDermWireTV: LEO Science & Tech Hub, Allergan/SkinBetter DREAM Initiative, San Diego Dermatology Symposium
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-leo-pharma-science-tech-hub-allerganskinbetter-dream-initiative-san-diego-dermatology-symposium/19856/Innovation Endeavors and the LEO Science & Tech Hub kick off a Deep Life Challenge program. Allergan Aesthetics, an AbbVie company, and Skinbetter Science launch a new long-term, educational initiative: The DREAM (Driving Racial Equity in Aesthetic Medicine) Initiative. The San Diego DermatologyWhat's your top travel destination dream?
https://practicaldermatology.com/topics/practice-management/whats-your-top-travel-destination-dream/20038/Misha Rosenbach, MD reflects on how the COVID-19 pandemic and concerns about climate change altered his perspective on travel destination dreams, as well as where he hopes to get back to one day.Drug Prices Soar, Amgen Files BLA for Biosimilar to Humira
https://practicaldermatology.com/topics/practice-management/dermwiretv-drug-prices-soar-amgen-files-bla-for-biosimilar-to-humira/18672/In this edition, Amgen Submits ABP 501—first Adalimumab biosimilar; prices for dermatology drugs jump and a survey explores patient knowledge of antibiotic resistance. Also, Almirall acquires Veltin from Sitefel/GSK.Choosing the Right Wound Dressing
https://practicaldermatology.com/conferences/masterclasses-in-dermatology-2025/choosing-the-right-wound-dressing/33017/Dennis Orgill, MD, PhD, a reconstructive plastic surgeon at Brigham and Women's Hospital in Boston, discusses the importance of choosing the right dressing for wound care at Masterclasses in Dermatology 2025 in Sarasota.Journal Club: S. Aureus-Driven AD Exacerbation
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-s-aureus-driven-ad-exacerbation/32404/Practical Dermatology Editorial Board member Christopher Bunick, MD, FAAD, discusses a recent Journal of Drugs in Dermatology article about the need for a novel treatment for S. aureus exacerbated atopic dermatitis with Adelaide Hebert, MD.Schachner LA, Andriessen A, Gonzalez ME, Lal K, Hebert AA, EThe Neuroimmune Mechanisms Driving Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37136/Practical Dermatology Editorial Board member Todd Schlesinger, MD, a board-certified dermatologist and Mohs surgeon with Epiphany Dermatology in Charleston, South Carolina, discusses the neuroimmune mechanisms that drive prurigo nodularis and how they differ from those in chronic pruritus and atopicFDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuNew Drug Developments in Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-drug-developments-in-dermatology/19971/Despite the COVID pandemic, the FDA had a nearly record year in drug approvals, says Vinod Nambudiri, MD, MBA, which has translated to new developments in dermatology. He discusses approvals of tirbanibulin 1% ointment for actinic keratoses and clascoterone cream 1% for acne, and how they fit into t